Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Poorly Differentiated Lung and GEP-NETs
NCT02250885Phase 2Completed
- Sponsor
- Gabrail Cancer Center Research
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in small cell lung cancer (SCLC), gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Gabrail Cancer Center Research. Started Aug 2014; status: completed.
02
Drugs
selinexor
03
Conditions
small cell lung cancer (SCLC)gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02250885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250885.